Therapy Optimisation for the Treatment of Hairy Cell Leukemia

Overview

The trial will test the effectiveness and toxicity of subcutaneous treatment with one cycle of cladribine in patients with hairy cell leukemia requiring treatment. They have to be untreated so far or may be pretreated with alpha-interferon.

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: N/A
    • Intervention Model: Single Group Assignment
    • Primary Purpose: Treatment
    • Masking: None (Open Label)
  • Study Primary Completion Date: December 2025

Detailed Description

Evaluation of remission status will take place 4 months after treatment. In addition, it will be tested whether patients with non-optimal response will have a benefit from a second cycle of cladribine. Non-optimal response is: patients with detectable residual disease; achievement of partial remission or detectable residual infiltration in the bone marrow.

Interventions

  • Drug: Cladribine s.c. injection, HCL treatment
    • Patients with hairy cell leukemia and the need for treatment are given cladribine 0.14 mg/kg for 5 consecutive days as a s. c bolus injection

Arms, Groups and Cohorts

  • Other: Cladribine s.c. injection, HCL treatment
    • Cladribine 0.14 mg/kg body weight for 5 consecutive days (d 1 – 5) as subcutaneous bolus injection for patients with hairy cell leukemia needing treatment

Clinical Trial Outcome Measures

Primary Measures

  • Determination of the rate of complete remissions after one cycle with subcutaneous cladribine
    • Time Frame: 4 months after treatment

Secondary Measures

  • Rate of complete remissions in patient who still have detectable residual disease
    • Time Frame: 4 months after treatment
    • A second cycle of cladribine after an interval of 4 months following the first cycle.

Participating in This Clinical Trial

Inclusion Criteria

  • Patients with histologically verified hairy cell leukemia – Presence of hairy cells in the bone marrow and peripheral blood detected by positive TRAP staining and / or co expression if cell surface antigens cluster of differentiation (CD) 19/CD25 or CD19/CD103 (b-ly7) – No previous cytostatic treatment (splenectomy or interferon treatment are allowed) – Need for treatment – Age at least 18 years old – General state of health according to WHO 0-2 – Current histology, not older than 6 months – Written consent by patient Exclusion Criteria:

  • Patients not fulfilling inclusion criteria above – Hairy cell leukemia variants (HCL-V): presence of lymphoid cells in bone marrow and / or peripheral blood, which have an intermediate morphology between hairy cells and prolymphocytes (negative TRAP staining and co- expression of CD19/CD103 without CD25 – Pretreatment with purine analogues or other chemotherapeutics – Concomitant corticosteroid therapy – Severe dysfunction of the heart (NYHA III or IV), the lung (WHO-Grade III or IV), the liver, except due to lymphoma (bilirubin > 2 mg/dl, alkaline phosphatase, glutamate-oxalacetate transaminase and glutamate-pyruvate transaminase > 2 x upper limit of normal), the kidneys (creatinin > 2 mg/dl or creatinine clearance < 50 ml/min), central nervous system diseases including psychoses. – Proven HIV infection – Active Hepatitis – Other florid infections – Anamnesis / diagnosis of other malignant disease (other than non-melanoma associated skin tumours or stage 0 in situ carcinoma of the cervix) – Pregnant or lactating women

Gender Eligibility: All

Minimum Age: 18 Years

Maximum Age: 90 Years

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • University of Giessen
  • Provider of Information About this Clinical Study
    • Principal Investigator: Jurgen Barth, Head of StiL Coordinating Center – University of Giessen
  • Overall Official(s)
    • Mathias J Rummel, Prof. Dr., Principal Investigator, Justus-Liebig-University | University Hospital | Medicinal Clinic IV
  • Overall Contact(s)
    • Mathias J Rummel, Prof PhD, +4964198542, mathias.rummel@innere.med.uni-giessen.de

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.